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THE REGULATION OF BIOTECHNICAL PATENTED




The expanding' American biotechnology2 industry advances signifi-
cant financial and humanitarian support for the United States.3 This
newly emerging business competes in the economic marketplace as a
profit-making enterprise.4 Furthermore, the industry's increased global-
ization5 assists United States competitiveness at a period when the
economy is faltering.7 Innovation8 in biotechnology also enhances the
* Lavanya Srivatsan, J.D. Candidate, American University, May 1992 and M.S.
Candidate, Johns Hopkins University, August 1992.
1. See G. S. BURRILL, BIOTECH 90: INTO THE NEXT DECADE 28 (1989) [hereinaf-
ter BURRILL] (noting that the biotechnology industry expects a twcnty-five fold in-
crease in sales in the next ten years).
2. See generally B. SATTELLE, BIOTECHNOLOGY IN PERSPECTIVE (1990) [hereinaf-
ter SATTELLE] (defining the uses of biotechnology). Biotechnology as used in this Com-
ment, refers to an industry which uses living organisms and their subcellular, cellular
or molecular components in environmental management technology and in the produc-
tion of health-related goods. Id. at 4. Although biotechnology is at the forefront of
present day applied science, many of the underlying biotechnological processes
originated thousands of years ago and are the basis for the production of bread, cheese,
beer, and wine. Id. at 6. Today, biotechnology comprises a full range of technologies in
the mapping of proteins, including recombinant Deoxyribonucleic Acid (DNA) and cell
fusion. See id. at 20 (outlining the uses of biotechnology); see also CENTER FOR SCI-
ENCE INFORMATION, BIOTECHNOLOGY, MICROBES AND THE ENVIRONMENT 207-19
[hereinafter MICROBES AND THE ENVIRONMENT] (citing the tools used in environmen-
tal biotechnology and profiling renowned biotechnology experts).
3. See infra notes 9, 11, 13 and accompanying text (acknowledging United States
efforts to preserve the environment and improve the Nation's health and food supply
through the use of biotechnology).
4. BURRILL, supra note 1, at 125-27. Public biotechnological companies received
$1.36 billion in annual total sales and S2.08 billion in annual total revenues. Id. at 125.
In addition, the industry employs an estimated sixty thousand people. Id. This employ-
ment figure is expected to triple in the next five years. Id. at 18.
5. Id. at 30. American biotechnology companies are active in foreign markets. Id.
More than fifty percent of all large companies and forty percent of all small companies
have sales in Western Europe, Japan, and Canada. Id. at 87. In addition, exports are
expected to soon equal imports. Id. at 87-88.
6. See BURRILL, supra note 1, at 144 (discussing the value of pharmaceutical com-
pounds and noting that they generate more than SI billion in domestic revenues).
7. See Greenwald, All Shook Up, TIME, Oct. 15, 1990, at 30 (noting an increased
unemployment rate and budget deficit).
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quality of human lives. 9 For example, advancements in genetic engi-
neering' ° have produced superior varieties of crops," vaccines,12 and
environmental control technologies. 13 Although ethical issues exist re-
garding the utilization of some types of biotechnology,' 4 the products of
8. Merges, Commercial Success & Patent Standards: Economic Perspectives on
Innovation, 76 CALIF. L. REV. 803, 807 (1988) [hereinafter Merges] (defining "innova-
tion" as the "functional version of a technology that is the first commercial product").
9. See generally MICROBES AND THE ENVIRONMENT, supra note 2, at 34-40 (main-
taining that science and technology are intimately related to health and the preserva-
tion of the ecological environment); Jaworski, Biotechnology: Prospects and Perspec-
tives, 34 U. KAN. L. REV. 655, 665-67, 660-61 (1986) [hereinafter Jaworski] (focusing
on current research in tissue culture and microbial pesticides). Congressional studies
indicate that "[t]he potential of biotechnology to improve the Nation's health, food
supply, and the quality of the environment leads logically to questions about the ade-
quacy of current funding levels." OFF. TECH. ASSESSMENT, NEW DEVELOPMENTS IN
BIOTECHNOLOGY, U.S. Investment in Biotechnology I (July 1988); see also Adler,
Controlling Applications of Biotechnology: A Critical Analysis of the Proposed Mora-
torium on Animal Patenting, 1 HARV. J.L. & TECH. 1, 17-22 (1988) (exploring bio-
technology including the subject of transgenic animals).
10. See generally SATTELLE, supra note 2, at 16 (evaluating the principles of ge-
netic engineering). Genetic engineering refers to the two techniques scientists use for
internally altering the genetic structure of an organism: cell fusion and recombinant
DNA. Id.; see Karney, Regulation of Genetic Engineering: Less Concern About
Frankensteins But Time for Action on Commercial Production, 12 U. TOL. L. REV.
815, 819 n.23 (1981) (explaining the underlying principles of genetic engineering).
11. See Jaworski, supra note 9, at 655-57 (discussing the uses of microbial pesti-
cides). Current technology can increase crop yields and decrease plant diseases and
pests. Id.
12. See SATTELLE, supra note 2, at 25 (detailing the use of biotechnology in the
development of vaccines). Vaccines enable the body to resist infection from diseases
and have, thus, served to alleviate human suffering. Id. For example, twenty years ago,
small pox was endemic in at least thirty different countries with more than ten million
people infected. Id. Today, however, this major disease has been virtually eliminated.
Id. Other viral diseases successfully treated by vaccines include polio, yellow fever,
rabies, and rubella (German measles). Id.
13. See Diamond v. Chakrabarty, 447 U.S. 303, 304 (1980) (describing the role of
bacterium capable of breaking down crude oil); MICROBES AND THE ENVIRONMENT,
supra note 2, at 43-62 (acknowledging the types of microbes released into the environ-
ment). Microorganisms can be employed to purify waste water in sewage disposal. Id.;
see SATTELLE, supra note 2, at 36-37 (addressing the role of microbes in environmental
control). In addition, the waste sulfite liquid from paper-making mills can be purified
by paecilomyces fungi. Id. at 37.
14. See Eisenberg, Patenting the Human Genome, 39 EMORY L.J. 721, 743-45
(1990) (suggesting that there are advantages in patenting parts of the human genome);
OFF. TECH. ASSESSMENT, REPORT BRIEF, NEW DEVELOPMENTS IN BIOTECHNOLOGY,
Ownership of Human Tissues and Cells - Special Report (March 1987) (defining the
laws that relate to the ownership of human biological materials). Four issues are par-
ticularly controversial. Id. The first issue concerns the ownership and control of scien-
tifically-generated information. Id. The second is the issue of mandatory genetic
screening. See Capron, Which Ills to Bear? Reevaluating the Threat of Modern Genet-
ics, 39 EMORY L.J. 665, 684-89 (1990) (elaborating on the ethical considerations asso-
ciated with genetic screening). The third concern is the use of genetic information for
reproductive decision making. See generally S. ELIAS & G. ANNAS, REPRODUCTIVE
GENETICS AND THE LAW (1987) (considering the legal issues surrounding the use of
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this industry are useful and essential. 18 In order to continue to provide
beneficial technology, this industry merits adequate patent1"
protection.1"
Patent laws are the primary means by which an inventor can protect
new technology from infringement 8 within the United States. 9 Patent
rights, 0 including the right to litigate for unauthorized use or manu-
facture, provide a critical competitive advantage in the biotechnology
industry."1 Development of one biotechnological product can cost mil-
genetic knowledge in selecting the characteristics of offspring); Knoppers & Sloss, Re-
cent Developments: Legislative Reforms in Reproductive Technology, 18 OTTAWA L.
REV. 663, 666-67 (1986) (examining emerging trends in the "medicalization" of repro-
duction and the "judicialization" of pregnancy in six countries). The fourth controversy
is the patenting of animals whose hereditary genes have been augmented by the addi-
tion of Deoxyribonucleic Acid (DNA) by humans. See H.R. 1556, 101st Cong., 2d
Sess. (1989); H.R. 1557, 101st Cong., 2d Sess. (1989) (addressing the scientific and
regulatory questions involved in the patenting of transgenic animals).
15. See supra notes 9, 11, 13 and accompanying text (noting the use of biotechnol-
ogy in the United States as a means by which to preserve the environment and to
enhance the Nation's health and food supply).
16. See 35 U.S.C. §§ 161, 171 (1988) (denoting the three main types of patents:
design, plant, and utility). Patents in biotechnology are an ancient practice. See Louis
Pasteur's Patents, 86 Sci. 327, Oct. 8, 1937, reprinted in 19 J. PAT. OFF. Soc'y 966
(1937). Many patents have been granted for the use of micro-organisms in fermenta-
tion and antibiotic production. Id. Louis Pasteur, for example, patented a number of
yeast-related inventions. Id.; see also Cameron Septic Tank Co. v. Village of Saratoga
Springs, 159 F.2d 453, 454-56 (2d Cir. 1908) (discussing the patent for the original
bacteria-using septic tank), cert. denied, 209 U.S. 548 (1908). This Comment focuses
on utility patents as related to biotechnology.
17. See Karney, Biotechnology Licensing, 8 LICENSING L. & Bus. REP. 1, 2 (1985)
(commenting on the legal implications of the commercialization of biotechnology);
Comment, Enemies to Innovation: Protecting Biotechnology Inventions, 5 SA'NTA
CLARA COMPUTER & HIGH TECH. L.J. 435, 436 (1989) (evaluating proprietary rights
in biotechnology).
18. Autogiro Co. v. United States, 384 F.2d 391, 400 (Cl. Ct. 1967). The critical
test in any infringement suit is whether the allegedly infringing device does "the same
work, in substantially the same way, and accomplish[es] substantially the same results"
as the patented product or processes. Id. The largest infringement suit to date occurred
when Polaroid Company was awarded $910 million in a suit against Kodak. N.Y.
Times, Oct. 22, 1990, at 4.
19. See 35 U.S.C. §§ 161, 171 (1988) (setting forth the means to enforce patent
infringement claims within the United States).
20. See infra notes 77-79 and accompanying text (assessing the protection provided
to an invention by the issuance of a patent).
21. See Note, Genetic Engineering: Innovation and Risk Minimization, 57 GEO.
WASH. L. REV. 100, 101-04 (1988) (commenting on the United States rising competi-
tive position in the biotechnology industry) [hereinafter Note, Genetic Engineering];
OFF. TECH. ASSESSMENT, NEW DEVELOPMENTS IN BIOTECHNOLOGY, PATENTING LIFE
29 (1989) [hereinafter Patenting Life] (noting that patent law is of increasing impor-
tance to biotechnology research and concluding that patent protection of biotechnology
products is an issue that presents a potential barrier to commercialization). Patents
benefit commercial entities by attracting venture capital and collaborative arrange-
ments. Id. Investors monitor biotechnological patent developments and often respond
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lions of dollars and span several years. 2 The patent system encourages
innovation 3 by providing an incentive to invest in such costly research
and development. 24 In the absence of effective intellectual property
rights, there would be little incentive to innovate in biotechnology. 25
Section 337 of the Omnibus Trade and Competitiveness Act
2 l
(OTCA) is the principal means by which an inventor may protect a
process patent27 from foreign infringement. Congress enacted the
OTCA, in part, in an effort to confront the issue of effective intellectual
quickly to the news. Id. For example, in 1980, Genentech set a Wall Street record for
the fastest price per share increase in an initial offering of stock. Id. at 30. The stock
price increased from $35.00 to $89.00 in twenty minutes. Id. That same year, Cetus set
the record for the largest sum of money raised in an initial public offering - $115
million. Id.
Since Italy began providing patent protection in 1978, Italian companies have in-
creased their market share of pharmaceutical products from thirty-six percent to forty-
four percent. Patents Stimulate the Development of Pharmaceutical Companies in It-
aly, 7 Int'l Trade Rep. (BNA) at 1201 (Aug. 1, 1990). Prior to 1978, only one Italian
company was among the fifty larger pharmaceutical companies in the world. Id. In
1991, there are seven. Id.
22. Process Patent Amendments of 1990: Hearings on H.R. 3957, 5664 Before the
Subcomm. on Courts, Intellectual Property and the Administration of Justice of the
House Comm. on the Judiciary, 101st Cong., 2d sess. (1990) [hereinafter Hearings]
(testimony of David Beir, Vice-President Government Affairs, Genentech, Inc.). The
current cost of developing a new biopharmaceutical therapy can easily exceed $230
million. Id. Amgen, Inc. spent eight years and over $100 million to develop erythro-
poietin, a drug useful to people suffering from anemia. See id. (testimony of Gordon
Binder, Chairman & Chief Executive Officer, Amgen, Inc.).
23. See Sony Corp. v. Universal City Studios, 464 U.S. 417, 426 (1984) (reasoning
that the monopoly privileges authorized by Congress are intended to motivate the crea-
tivity of authors and inventors by means of a "reward"); STAFF OF SENATE COMM. ON
THE JUDICIARY, 85th CONG., 2d SEss., STUDY OF THE SUBCOMM. ON PATENTS, TRADE-
MARKS, AND COPYRIGHTS - AN ECONOMIC REVIEW OF THE PATENT SYSTEM 15
(Comm. Print 1958) (providing a general discussion of the relationship between inno-
vation and patents and of the "exchange for secrets thesis" of the patent system by the
noted economist Fritz Machlup); see also Merges, supra note 8, at 807 (contending
that the patent system encourages and rewards innovation).
24. See supra note 22 (addressing the costliness of biotechnology research and
development).
25. Merges, supra note 8, at 876 (detailing the history of patent law); see Mans-
field, Patents and Innovation: An Empirical Study, 32 MGMT. SCi. 173, 174 (1986)
(interpreting the results of an empirical study regarding the interrelationship between
patents and innovation).
26. Omnibus Trade and Competitiveness Act of 1988, 19 U.S.C. § 1337(a)-U)
(1988) [hereinafter OTCA]; see 134 CONG. REC. H5520 (daily ed. July 13, 1988)
(referencing the debate over the OTCA amendments). Section 337 of the Tariff Act of
1930 has carried over to present day use despite changes in the actual section numbers;
thus, section 1337 is generally referred to as section 337. Note, Overview of Amend-
ments in the 1988 Omnibus Trade Bill: Sections 301, "Super 301" and 337, 730
B.Y.U.L. REV. 729, 729 n.1 (1989).
27. See supra note 16 and accompanying text (focusing on the three patent
categories).
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property protection.2s The OTCA was intended to eliminate the unau-
thorized importation of patented goods into the United States." The
biotechnology industry depends on the OTCA to uphold the value of its
patents and prevent infringement by foreign manufacturers.3"
This Comment discusses the effectiveness of patent protection under
the OTCA. The Court of Appeals for the Federal Circuit" clarified the
scope of the OTCA in Amgen, Inc. v. United States International
Trade Commission." The court held that the OTCA does not prohibit
the importation of foreign goods produced by a process in which a
starting product claimed in a United States patent is used.33 The court
declined to assess the adequacy of available patent protection, reason-
ing that such an issue should be resolved by the legislature.- Amgen
illustrates the inadequacy of biotechnical patent protection provided by
the OTCA.
Part I of this Comment discusses the purpose and privileges of patent
laws. Part I also briefly explores the dependence of the biotechnology
industry on patents. Part II details the evolution of the OTCA and the
limited protection accorded by section 337 against the infringement of
process patents. Part III discusses the underlying issues and implica-
tions of the Amgen decision. Part IV analyzes the scope of section 337
of the OTCA and illustrates the failure of the OTCA to stimulate in-
novation and provide adequate protection of intellectual property
rights. This section also addresses the consequences of such deficiencies
on the biotechnology industry. Finally, Part V urges Congress to
strengthen and extend the OTCA's reach in an effort to protect all
types of patent claims. Part V contends that such strengthening would
advance fundamental goals that are the essence of intellectual property
rights.
28. See infra notes 102-105 (discussing the reasons the OTCA was enacted).
29. See Newman, infra note 96, at 575-80 (reviewing the history of the OTCA).
30. See Hearings, supra note 22, at 2-7 (demonstrating the importance of patents
to the biotechnology industry).
31. See Merges, supra note 8, at 806 (noting that Congress established the Court
of Appeals for the Federal Circuit in 1982 in an effort to improve and create conform-
ity in the patent system).
32. 902 F.2d 1532 (Fed. Cir. 1990).
33. Id. at 1539.
34. Id. at 1540.
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I. AN OVERVIEW OF PATENT LAW
A. PATENTS ENDEAVOR TO PROMOTE INNOVATION IN
BIOTECHNOLOGY
The Constitution provides the basis for the concept of American in-
tellectual property rights.3 5 Article I of the Constitution grants Con-
gress broad legislative power "[t]o promote the [p]rogress of [s]cience
and useful [a]rts, by securing for limited [t]imes to [a]uthors and
[i]nventors the exclusive right to their respective [w]ritings and
[d]iscoveries." 36 Congress chose to achieve this goal by issuing patents
to deserving authors and inventors.37
The granting of patents advances the collective goals of disclosure
and reward.38 Inventors disclose their inventions to society, and in re-
turn society rewards such efforts through the issuance of limited prop-
erty rights in each invention .3  This reciprocal relationship is essential
for three reasons. First, the development of new technologies alleviates
the impact of increased foreign competition.40 New technology fosters
United States growth and productivity. 41 Second, society as a whole
benefits by the introduction of new inventions.42 Third, the disclosure
and reward method promotes further innovation because researchers
can improve on the patented inventions of others. 3
Some commentators erroneously assert that the patent system does
not impact the development of innovation.44 These critics allege that
35. U.S. CONST. art. I, § 8, cl. 8. The concept of intellectual property protection
originates from English common law. Patenting Life, supra note 21, at 3.
36. U.S. CONST. art. I, § 8, cl. 8.
37. 35 U.S.C. §§ 100-104 (1988).
38. Merges, supra note 8, at 808; see also Waltersheid, The Need for a Uniform
Government Patent Policy: The D.O.E. Example, 3 HARV. J.L. & TECH. 103, 184
(1990) (emphasizing the tendency of courts to favor disclosure as the ultimate goal of
the federal patent system).
39. Merges, supra note 8, at 809.
40. See Clark, The Future of Patent-Based Investigations Under Section 337 After
the Omnibus Trade and Competitiveness Act of 1988, 38 AM. U.L. REv. 1149, 1150-
51 (1989) [hereinafter Clark] (characterizing the effects of increased technological de-
velopment); see also Perry, The Surprising New Power of Patents, FORTUNE, June 23,
1986, at 57 (acknowledging the recent growth in the financial power of patents) [here-
inafter Perry].
41. Clark, supra note 40, at 1150-51.
42. See Diamond v. Chakrabarty, 447 U.S. 303, 307 (1980) (maintaining that the
introduction of new technologies provides increased employment opportunities and im-
provements in the standard of living).
43. Merges, supra note 8, at 808. A researcher is able to examine and improve
upon another's invention, thus, fostering additional product innovation. Id.
44. See Note, Genetic Engineering, supra note 21, at 101 (outlining the arguments
of patent reform critics).
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the patent system results in commercial monopolization 40 and frus-
trates technological advancement. 46 This argument, however, is flawed;
a patent in itself does not constitute a monopoly.47 Moreover, a paten-
tee engaging in monopolistic behavior, in acquiring or using the patent,
is accountable to antitrust laws.48 Critics also contend that the general
economic climate impacts the development of technology more than
any other specific measure.49 This reasoning is inconclusive because it
fails to address specific industry issues.
Patents are a critical element in promoting innovation in biotechnol-
ogy.50 The average biotechnology firm spends a tremendous amount of
funds on research and development.5" Commercial biotechnology, more
than any other high technology industry, depends on research and de-
velopment to generate revenue.52 A company generates income on pat-
ented products through exclusivity in marketing. 3 Patents offer the op-
45. Id.
46. Id.
47. United States v. Dubilier Condenser Corp., 289 U.S. 178, 186 (1933). In
Dubilier Condenser Corp., the Supreme Court reasoned that an inventor does not de-
prive society of anything that it enjoyed prior to his or her discovery; instead, the inven-
tor aids society by "adding to the sum of human knowledge." Id.
48. United States v. Studiengelsellschaft Kohle, 670 F.2d 1122, 1127-28, 1133-34
(D.C. Cir. 1981).
49. Bus. WEEK, June 15, 1990, at 35.
50. See Patent Life, supra note 21, at 3 (asserting that patents are vital to protect-
ing commercial interests in biotechnology); Eisenberg, Patents and the Progress of Sci-
ence; Exclusive Rights and Experimental Use, 56 U. CHI. L. REv. 1017, 1045-46
(1989) (noting that although patents are justified as a means of providing incentives,
there are no clear answers to the empirical questions of when these incentives are
needed); see also BURRILL, supra note 1, at 94-95 (reviewing the number of patents
held by various biotechnological firms).
51. See Hearings, supra note 22, at I (testimony of Robert Armitage, Vice Presi-
dent, The Upjohn Company) (estimating that Upjohn's expenditures on research for
1990 amounted to more than $400 million). The start-up costs of a biotechnological
company, which include basic research and development, are usually so high that most
companies can only achieve profitability as they expand. BURRILL., supra note 1, at
104. Research and development costs vary depending on the size of the company. Id. at
107. Small companies spend 40 percent of total costs while large companies spend 41
percent of total costs. Id. For example, research costs can amount to as much as $8.6
million per year. Id.; see also Bus. WEEK, supra note 49, at 207-08 (providing research
and development statistics for the pharmaceutical industry). The United States bio-
technology industry spends more than S2.0 billion annually in research and develop-
ment. U.S. Investment in Biotechnology, supra note 9, at 3.
52. See BURRILL, supra note 1, at 28 (proposing that biotechnology companies are
supported and driven by the potential for future commercial success). Two-thirds of the
biotechnology industry's total revenue is generated by product sales. Id. Large compa-
nies typically earn as much as S57.7 million in sales. Id. at 105. Contract and collabo-
rative research are the other major sources of revenue. Id.
53. See Patenting Life, supra note 21, at 3 (stressing the vital role of patents in
protecting commercial interests in biotechnology).
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portunity to procure substantial profits from new inventions. 54 The
reward of a patent, thus, justifies the enormous financial risks of re-
search and development.55 Adequate patent protection is, therefore,
crucial in an effort to encourage innovation in biotechnology.06 The
lack of adequate patent protection jeopardizes essential economic and
humanitarian benefits provided by this industry.
B. PATENT STANDARDS & LITIGATION RIGHTS
An invention must meet specific criteria to merit a patent award. 57
The invention must be new,"8 non-obvious, 59 and useful.60 The subject
matter of the invention must also be considered patentable."' Product
and process patents are the two predominant categories of patentable
subject matter.62 A product is a physical entity such as a machine,
54. See BURRILL, supra note 1, at 144 (opining that "[tihere has never been on the
face of this earth a product more profitable than a blockbuster pill"). Furthermore,
"[a]n effective pill is probably one of the best creations of capitalism because ... the
customer receives incredible value, and the reward to the investor who took risk to
create that pill is enormous." Id.
55. Id.
56. See id. at 210 (noting that "[i]f the invention is truly valuable and cannot be
protected except by a patent, then a patent is well worth having, despite the expense")
(quoting Howard C. Birndorf, President of Progenx Inc.).
57. 35 U.S.C. §§ 100-04 (1988). Title 35 delineates the measures that must be
taken in securing a patent application and grant. Id.
58. Id. at § 102(a)-(g). An invention is not patentable under this section if it is
described in a printed publication or another patent prior to the patent applicant's date
of invention, or if it is otherwise known or used in the United States prior to that date.
Id. There are several other detailed provisions denoting when an invention is not con-
sidered novel. Id.
59. Id. at § 103; see Graham v. John Deere Co., 383 U.S. 1, 14-17 (1966) (con-
cluding that section 103 requires an independent determination of nonobviousness as a
prerequisite to patentability). Three indicia are considered in determining nonobvious-
ness. Id. at 17. First, the state of the prior art before the invention must be found. Id.
Second, the ordinary level of skill in the inventor's field is assessed. Id. Third, the
difference between the invention and the prior art is examined. Id.
60. 35 U.S.C. § 101 (1988). The utility requirement is derived from two sources.
First, the Constitution mandates protection for the "useful Arts." U.S. CONST. art 1, §
8, cl. 8. Second, the Patent Act specifies that an invention must be useful. 35 U.S.C. §
101 (1988). An invention must be of some benefit qualitatively, but no particular quan-
tum benefit is required. Anderson v. Natta, 480 F.2d 1392, 1395 (C.C.P.A. 1973).
Utility cannot be presumed. 35 U.S.C. § 112 (1988). It must be disclosed as an inte-
gral part of the patent specification. Id.
61. 35 U.S.C. § 101 (1988). "Whoever invents or discovers any new and useful
process, machine, manufacture, or composition of matter, or any new and useful im-
provement thereof, may obtain a patent therefor, subject to the conditions and require-
ments of this title." Id.
62. See D. CHISUM, PATENTS: A TREATISE ON THE LAW OF PATENTABILITY, VALID-
ITY AND INFRINGEMENT §§ 1.02-.03 (1988) [hereinafter CHISUM] (discussing the dif-
ferent categories of patents).
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manufacture or composition."3 A process, however, is defined as a
"means to an end."' ' For example, assume an invention contains a pat-
ented process that isolates a precise protein through a sequence of steps
incorporated in a machine. The machine itself is patentable as a pro-
cess patent. 5 Essential starting materials may or may not be patenta-
ble.66 Additionally, the end-product of the process - the isolated protein
- may warrant an independent product patent.67
A patent, regardless of its classification, accords particular privileges
to its owner.68 It grants a limited property right6" in the invention for a
term of seventeen years.7 0 A patentee71 is entitled to litigate72 against
unauthorized individuals" who make, use, or sell, the invention within
the United States. 4 A patent entitles a patentee to bring suit against a
foreign importer that manufactures an American product patent
abroad and sells that product in the United States.7 6 The patentee has
a viable cause of action in such a case because the patent is materially
infringed in the United States. 6
Prior to the OTCA, an infringement suit could not be filed against
foreign manufacturers who made, used, or sold an American process
patent abroad and then exported the resulting end-product into the
63. Id. § 1.02.
64. Id. § 1.03.
65. 35 U.S.C. §§ 100-01 (1988).
66. CHISUM, supra note 62, § 1.02.
67. Id. Naturally occurring substances are not usually considered patentable. Dia-
mond v. Chakrabarty, 447 U.S. 303, 309 (1980). Substances or organisms that have
been humanly modified may qualify for patentability. Id. at 309-10.
68. See 35 U.S.C. §§ 261-62 (1988) (delineating the rights of the patentee).
69. See 35 U.S.C. § 261 (1988) (stating that patents have the attributes of per-
sonal property).
70. Id. § 154. Section 154, entitled "Contents and term of patent," states:
Every patent shall contain a short title of the invention and a grant to the paten-
tee, his heirs or assigns, for the term of seventeen years, subject to the payment
of fees as provided for in this title, of the right to exclude others from making,
using, or selling the invention throughout the United States ....
Id.
71. See id. § 100(d) (defining the term "patentee" as including the individual to
whom the patent was issued as well as any successors in title). Id.
72. See id. § 281 (stating that a patentee is entitled to bring a civil action for
patent infringement).
73. See id. § 271(a) (providing that "whoever without authority makes, uses, or
sells any patented invention, within the United States during the term of the patent
therefor, infringes the patent."). Even an innocent infringer who develops the same
invention independently can be prevented from using the patent. Id. § 154.
74. Deepsouth Packing Co. v. Laitram Corp., 406 U.S. 518, 531 (1972) (holding




AM. U.J. INT'L L. & POL'Y
United States. 7 These foreign manufacturers were not concerned with
infringement actions because the physical infringement of the process
patent occurred outside the United States and American patent laws
did not provide a remedy in such a case.7 8 Meanwhile, an injured pro-
cess patentee's sole recourse was existing trade legislation allowing a
claim for an unfair action. 9 Injured patentees filed suits under section
337 of the Tariff Act of 193080 at the International Trade Commission
(ITC).8'
II. EVOLUTION OF THE OTCA
A. THE INEFFECTIVE PRE-OTCA REMEDY: SECTION 337 OF THE
TARIFF ACT
Section 337 of the Tariff Act of 19302 (Tariff Act) is the predeces-
sor of section 337 of the OTCA.a3 The Tariff Act's drafters intended to
stimulate the growth of industry and protect American labor by
preventing unfair tactics or methods of competition in the importation
77. See Tariff Act of 1930, 19 U.S.C. § 1337 (1982 & Supp. IV 1986), amended
by OTCA, 19 U.S.C. § 1342 (1988) (denoting the rights available to the patentee).
78. Id. The Contributory Infringement Doctrine also did not provide the patentee
with a form of relief. Id. Contributory infringement requires direct infringement "un-
authorized use of the process within the United States." Deepsouth Packing Co. v.
Laitram Corp., 406 U.S. 518, 531 (1972). A manufacturer using an infringing process
patent outside the United States was able to export that product into the United States
without directly infringing the process patent. Id.
79. See 19 U.S.C. § 1337 (1988) (demonstrating the inadequate protection ac-
corded by federal law). Section 337(a) of the Tariff Act of 1930, as amended, prohibits
unfair methods of competition and unfair acts regarding imports as follows:
Unfair methods of competition and unfair acts in the importation of articles into
the United States, or in their sale by the owner, importer, consignee, or agent of
either, the effect or tendency of which is to destroy or substantially injure an
industry, efficiently and economically operated, in the United States, or to pre-
vent the establishment of such an industry, or to restrain or monopolize trade or
commerce in the United States, are declared unlawful, and when found by the
Commission to exist shall be dealt with, in addition to any other provisions of
law, as provided in this section.
Id.
80. Id.
81. See id. § 1330. (describing the organization of the International Trade Com-
mission). The administrative process for obtaining protection under section 337 is
designed to provide efficient and expeditious relief. See H. KAYE, P. PLAIA & H.
HERTZBERG, INTERNATIONAL TRADE PRACTICE § 2.02 (1987) [hereinafter INTERNA-
TIONAL TRADE PRACTICE] (detailing the establishment of Revenue Commission of
1865).
82. Tariff Act of 1930, 19 U.S.C. § 1337 (1982 & Supp. IV 1986), amended by
OTCA, 19 U.S.C. § 1342, at 1212-15 (1988).
83. 19 U.S.C. § 1337(a) (1988).
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of articles into the United States. 4 The drafters sought to hold foreign
importers to the same standards of fairness that were expected of do-
mestic industries.85 Thus, the Tariff Act prohibited foreign importers
from engaging in unfair acts that damage, restrain or inhibit United
States businesses.86 In interpreting the Tariff Act, courts included pat-
ent infringement within the meaning of an unfair act.87
The designation of a patent infringement as an unfair act, however,
did not protect all patentees, as demonstrated by the case In re Amtorg
Trading Corp.8 8 The court in Amtorg held that the importation of a
product produced outside the United States using a patented process
was not an infringement under United States patent law.89 In response,
Congress amended section 337 of the Tariff Act to prohibit the unau-
thorized importation of products, produced under a valid United States
process patent.90 This statute gave the ITC91 two options upon estab-
lishment of the unlawful act. 2 First, the ITC had the authority to ex-
clude articles from entry.93 Second, the ITC had the power to order
persons, over whom it had jurisdiction, to cease and desist from import-
84. Wineburg, Litigating Intellectual Property Disputes at the International Trade
Commission, 68 J. PAT. OFF. Soc'Y 473, 473-74 (1986). Section 337 reaches unfair
acts involving a wide variety of intellectual property causes of action as well as many
business torts and antitrust problems. Id. at 477. The most commonly asserted unfair
trade practice, however, is unauthorized patent use. Id.
85. INTERNATIONAL TRADE PRACTICE, supra note 81, at § 4.01.
86. See section 337(a) of the Tariff Act of 1930, 19 U.S.C. § 1337 (1988) (provid-
ing the standards by which to judge the damage of an unfair act).
87. Frischer & Co. v. Bakelite Corp., 39 F.2d 247, 259-60 (C.C.P.A.), cert. denied,
282 U.S. 852 (1930).
88. In re Amtorg Trading Corp., 75 F.2d 826, 832-34 (C.C.P.A.), cert. denied, 296
U.S. 576 (1935).
89. Id. The court noted that protection granted by a United States patent right is
confined to the United States and infringement of this right cannot be established by
acts performed in a foreign country. Id. at 831-32.
90. See 19 U.S.C. § 1337(a) (1982) (repealed 1988) (describing that imported
products made by a process covered by a claim of a valid United States patent are
governed by that patent just as competing domestic products are covered).
91. See supra note 81 and accompanying text (providing background information
on the ITC). Anyone, including a nonparty, who was adversely affected by the ITC's
final determination could appeal the decision to the Court of Appeals for the Federal
Circuit. 19 U.S.C. § 1337(c) (Supp. IV 1982).
92. 19 U.S.C. § 1337(c) (Supp. III 1985). Section 337 requires establishment of
the following:
(1) an unfair act of authorized use and importation;
(2) existence of a domestic industry exploiting the patent, or the potential for
such an industry;
(3) that such U.S. industry, if existing, is efficient and economically operated;
(4) an effect or tendency of such importation is to destroy or substantially injure
that industry, or prevent the establishment of such an industry.
Id.
93. Id. § 1337(d).
19921
AM. U.J. INT'L L. & POL'Y
ing such articles.94 The ITC's ruling was subject to a policy review by
the President. 5
Despite congressional intent, the Tariff Act provided minimal relief
to process patentees against infringing imports.9 In addition, parties
found the Tariff Act to be cumbersome, costly, and ineffectiveY7 More-
over, injured process patentees still could not bring infringement suits
under statutory patent laws.98 Claims could only be filed under the
trade laws.9" In response to these inadequacies, Congress enacted the
OTCA100 to improve the Tariff Act and to extend the reach of patent
protection. 01
B. OTCA AMENDS PATENT LAW AND THE TARIFF ACT
The OTCA resulted from more than three years of deliberation by
both Congress and the Reagan Administration.0 2 Senator Lautenberg,
one of the original sponsors of the OTCA, emphasized that the intent
of the Act was to encourage innovation and enhance American indus-
try's ability to compete globally. 103 Congress intended the OTCA to
94. Id. § 1337(f).
95. Id. § 1337(j). Parties who were adversely affected by a Presidential veto did not
have the remedy of appeal. Duracell, Inc. v. United States Int'l Trade Comm'n, 778
F.2d 1578, 1581-82 (Fed. Cir. 1985).
96. See Newman, The Amendments to Section 337: Increased Protection for Intel-
lectual Property Rights, 20 LAW & POL'Y INT'L Bus. 571, 573-87 (1989) [hereinafter
Newman] (discussing the inadequacies of the Tariff Act of 1930 and detailing subse-
quent amendments to increase its effectiveness).
97. Id.
98. Id. at 572.
99. Id.
100. OTCA, 19 U.S.C. § 1337 (1988).
101. NEWMAN, supra note 96, at 572-73.
102. Id. at 572. The amendments reflect a concern that section 337 was becoming
increasingly ineffective "in addressing the growing problems being faced by U.S. com-
panies." H.R. REP. No. 40, 100th Cong., Ist Sess., pt. 1, at 155 (1987).
103. 134 CONG. REC. S10,714 (daily ed. Aug. 3, 1988) (statement of Sen.
Lautenberg). According to Senator Lautenberg:
[a] continuing goal of Congress is to encourage innovation by providing mean-
ingful protection for the inventions and discoveries of American inventors and for
the manufacture of innovative products made by American workers. The emerg-
ing biotechnology industry has pioneered a revolutionary genetic engineering
technology that produces recombinantly derived materials used to make previ-
ously unavailable products.
With respect to section 1342 of the Trade Act (title 19), this bill reenacts
prior section 337a of the Tariff Act of 1930 (as 337(a)(1)) which addresses pro-
tection of United States businesses from importation of products made outside of
the United States by a process covered by claim of a United States patent.
Section 337(a)(1) (a reenactment of section 337a) will provide the assistance
necessary for emerging U.S. industries, such as the biotechnology industry, to
compete in a marketplace without interference due to the unfair acts of foreign
competitors. The continued broad jurisdiction of the International Trade Coin-
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counter an escalating trade deficit and the country's falling competitive
position.10 4 Congress had realized that international competitiveness de-
pends largely on the technological developments of domestic
industries. 10 5
The OTCA revised both statutory patent law and the Tariff Act of
1930.106 These revisions were designed to stimulate innovation by ex-
panding intellectual property protection. 10 7 The OTCA expands section
154 of the Tariff Act by prohibiting the use or sale within the United
States, or importation into the United States, of products made by an
American process patent."°8 The OTCA also allows an injured process
patentee to bring an infringement suit for an injunction or damages in
federal district court. 0 9
Section 337 of the OTCA's description of unlawful activities remains
essentially the same as the Tariff Act." 0 The OTCA altered, however,
several central provisions."' The drafters revised these provisions in or-
mission will help U.S. industry address the unfair activity of foreign competitors
who, for example, import products manufactured using patented genetic engi-
neering technology. Merely moving manufacture offshore does not absolve the
wrongdoer from the requirement to compete fairly. This Trade Act protection
prohibits the foreign enterprise from taking jobs from American workers by do-
ing offshore that which they could not lawfully do in the United States.
Id. (Emphasis added.)
104. See Clark, Patent Based Investigations Under Section 337 After the Omnibus
Trade and Competitiveness Act of 1988, 38 Am. U.L. REv. 1149, 1150-51 (1989)
[hereinafter Clark] (noting that almost every country in the world has investments in
American industry).
105. Id. at 1151.
106. OTCA, 19 U.S.C. § 1337(a)(2)(B) (1988), amending 35 U.S.C. § 154
(1952). Title IX, subtitle A of the OTCA amended the Patent Act to extend protection
against infringement to process patentees. Id. Under the OTCA, "unlawful activities"
include the following:
The importation into the United States, the sale for importation, or the sale
within the United States after importation by the owner, importer, or consignee,
of articles that ... are made, produced, processed, or mined under, or by means
of, a process covered by the claims of a valid and enforceable United States
patent.
Id. § 1342(a)(1)(B); see 134 CONG. REc. H5,520 (daily ed. July 13, 1988) (referenc-
ing the debate over the OTCA amendments).
107. OTCA, 19 U.S.C. § 1l01(a)(10) (1988).
108. Id. § 9002; see Note, supra note 26, at 739-44 (outlining the new and old
provisions of section 337).
109. OTCA, 19 U.S.C. § 9006(c) (1988). Section 9006 expressly preserves the
remedies available under the Tariff Act. Id.
110. The Tariff Act of 1930, 19 U.S.C. § 337 (1982 & Supp. IV 1986); see New-
man, supra note 100, at 575 (providing a history of the Tariff Act of 1930 and compar-
ing it to the OTCA).
111. OTCA, 19 U.S.C. § 1337(a). Specifically, the new section 337 mandates that
"[i]f intellectual property rights are registered under United States law, injury need
not be shown." Id. The showing of injury by a United States industry is still required,
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der to ease a patent holder's burden of proving foreign process patent
infringement and to limit the remedies against United States parties.' 12
Congress recognized the need to protect American industries from un-
fair acts and process patent infringements by improving the scope of
patent law and the provisions of the Tariff Act."'
III. THE EFFECT OF THE OTCA ON AMGEN
Even though Congress conceived OTCA to protect against intellec-
tual property piracy and promote United States industry," 4 the Court
of Appeals for the Federal Circuit cast doubt upon the OTCA's ability
to address these concerns with its decision in Amgen, Inc. v. United
States Int'l Trade Comm'n."15
A. BACKGROUND OF Amgen
Amgen, Inc. is a company dedicated to the development of human
pharmaceuticals through the advancement of recombinant DNA"'
but the requirement that it must be an economic injury was eliminated. Id. §
1337(a)(3).
112. See 134 CONG. REC. H5,520, H5,529 (daily ed. July 13, 1988) (statement of
Rep. Fish) (emphasizing the importance of process patent protection to the stability of
United States industry).
113. Id.
114. See id. (supporting of the enactment of the OTCA amendments); Newman,
supra note 100, at 575 (providing arguments in favor of the OTCA amendments).
115. 902 F.2d at 1532. This case was one of first impression for the court. See id.
at 1540 (acknowledging that Congress had not contemplated the specific patent issue
presented).
116. See Engineering, Genetic Style, 15 NAT'L J. 2097, Oct. 15, 1983 (1983) (de-
fining recombinant deoxyribonucleic acid (DNA) and discussing its use in genetic engi-
neering); see also D. VOET & J. VOET, BIOCHEMISTRY 772-86 (1990) [hereinafter Bio-
CHEMISTRY] (providing a detailed discussion of DNA); SAT1ELLE, supra note 2, at 20
(describing recombinant DNA technology); L. STRYER, BIOCHEMISTRY 117 (3d ed.
1988) (specifying the function and structure of enzymatic and protein activity in re-
combinant DNA); Dressler & Potter, Molecular Mechanisms in Genetic Recombina-
tion, ANN. REV. BIOCHEMISTRY 727, 727-61 (1982) (detailing current innovations in
gene splicing and recombination); Stahl, Genetic Recombination, Scl. AM., Feb., 1987,
at 90-101 (discussing the recent developments in genetic engineering).
Genes contain information necessary for the composition of a particular protein. BIo-
CHEMISTRY, supra, at 772-86. The recombinant-DNA method begins with the isolation
of a specific genetic sequence. Id. Scientists look for a specific trait in a donor organ-
ism's genes for transfer to a host organism and isolate the specific segment of the do-
nor's DNA that produces that trait. Id. These segments are then joined with other
fragments of DNA. Id. The reconstructed DNA is transferred to a microorganism. Id.
Viral DNA was first spliced into recombinant molecules by Paul Berg of Stanford
University in 1972. MICROBES AND THE ENVIRONMENT, supra note 2, at 191. In 1973,
Stanley Cohen and Herbert Boyer launched the era of biotechnology when they spliced
toad genes and recombined bacterial DNA. Id.
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technology."17 Amgen invested eight years and over $100 million to de-
velop recombinant erythropoietin" 8 (rEPO)." 8' This product helps to
treat patients suffering from anemia.120 Scientists at Amgen unraveled
the genetic mystery of erythropoitin (EPO).' 2 ' Amgen successfully pro-
duced genetically-altered cells (host cells) capable of manufacturing
large amounts of EPO far more quickly than normal human cells.122
Because the amount of EPO available free in nature is minimal, the
unique host cells and recombinant DNA sequences are vital as starting
materials to manufacture rEPO for pharmaceutical purposes . 23
Amgen succeeded in obtaining a patent for its rEPO developments in
1987.124 The patent, known as '008, protects Amgen's developments in
recombinant DNA sequences and host cells used to produce rEPO. 125
Amgen's claims, however, do not extend to the product rEPO itself, to
any process of making rEPO, or to any other related process.'20 Patent
laws did not allow rEPO itself to be patented. 27 In sum, Amgen has a
patent only on the starting material needed to make rEPO. Unauthor-
ized use of Amgen's starting material within the United States consti-
tutes unlawful infringement. 28
117. Hearings, supra note 22, at 2 (statement of Gordon Binder, Chairman and
Chief Executive Officer, Amgen, Inc.).
118. See Amgen, Inc., 902 F.2d at 1533 (describing "erythropoietin" as a protein
that controls the synthesis of red blood cells in bone marrow).
119. Id.; see BURRILL, supra note 1, at 195 (observing that researchers have re-
ported that the production of recombinant products, as compared to other biotech prod-
ucts, is particularly difficult and expensive).
120. Amgen, Inc., 902 F.2d at 1533.
121. See Hearings, supra note 22, at 3 (statement of Gordon Binder, Chairman
and Chief Executive Officer, Amgen, Inc.).
122. Amgen, Inc., 902 F.2d at 1533.
123. Hearings, supra note 22, at 3. Before the development of host cells, erythro-
poietin was found only in minute quantities in urine. Id. It still cannot be purified in
amounts large enough for human use. Id.
124. Id. at 4. Amgen obtained United States Patent Number 4,703,008 (the '008
patent). Amgen, Inc., 902 F.2d at 1533.
125. Amgen, Inc., 902 F.2d at 1533-34. The "claims" section of any patent is im-
portant to define the exact property rights of a patentee. See Duft, Patent Infringement
and Biotechnology, 16 AIPLA Q.J. 339, 343-89 (1988) (explaining claim interpreta-
tion, the basis for infringement, and available remedies).
126. Amgen, Inc., 902 F.2d at 1533-34. The original patent application contained
process claims for the production of rEPO, but the Patent and Trademark Office re-
jected these claims. Id. These claims were considered to be for the application of an old
process to new starting materials. Id. Thus, the process itself was not patentable. In re
Durden, 763 F.2d 1406, 1411 (Fed. Cir. 1985).
127. Amgen, Inc., 902 F.2d at 1533-34.
128. Id. at 1538.
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In January 1988, Amgen initiated an unfair action129 suit before the
ITC against Chugai Pharmaceutical Co. of Japan (Chugai) and its
subsidiary, Chugai Pharma U.S.A., alleging that they had imported
rEPO manufactured in Japan. 30 Amgen claimed that Chugai used re-
combinant technology protected by patent and maintained that the
rEPO Chugai imported was made by a process, which if practiced in
the United States, would infringe the '008 patent.131 During the ensu-
ing ITC investigation,' 32 Congress passed the OTCA, 33 thus, Amgen's
complaint fell under the jurisdiction of section 337 of the new
OTCA.1 4
The primary question was whether Chugai engaged in unfair activi-
ties as defined by section 337 of the OTCA." 53 The Court of Appeals
for the Federal Circuit stated the issue as whether Chugai's imported
rEPO was made employing a process protected by a claim of Amgen's
patent.136 Thus, the answer depended upon the court's interpretation of
section 337's language concerning "a process covered by the claims of a
... patent."' 37 The court employed a two-step analytical approach to
determine the scope of section 337 and to interpret the relevant lan-
guage." 8 The court first examined the plain meaning of the OTCA's
statutory language to determine whether section 337's language prohib-
ited the importation of products that used patented American starting
materials. 139 After finding that the plain language of section 337 only
referred to process claims and not patented starting materials, 40 the
court used a second approach. The court focused on the OTCA's legis-
lative history in an effort to determine the scope of section 337.141
129. See supra notes 82-113 and accompanying text (defining the term "unfair
action").
130. Amgen, Inc., 902 F.2d at 1534.
131. Id. at 1534, 1538.
132. Id. at 1534; see 19 C.F.R. § 210.53 (1988) (detailing the infringement claim
procedure). When a complaint is filed, an administrative law judge at the ITC holds a
preliminary hearing to examine the unfair acts and economic aspects of the foreign
importation or sale. id.
133. OTCA, 19 U.S.C. § 133 7 (a)-j) (1988). The OTCA was passed on August
23, 1988. Amgen, Inc., 902 F.2d at 1534.
134. Id.
135. Id.
136. Id. Amgen requested that the issue be phrased as "whether section
1337(a)(1)(B)(ii) requires conventional process claims." Id. The court was limited,
however, to using only the language contained in the OTCA. Id.
137. Id. at 1538.
138. Id.
139. Id.




The Court of Appeals for the Federal Circuit held that section 337
of the OTCA applies only to patents containing a process claim.1 42 The
court found that the OTCA does not prohibit the importation of arti-
cles made by a process in which a product claimed in a United States
patent is used. 143 The court ruled that Chugai's rEPO was not made
employing a process protected by a claim of Amgen's patent. 144
Chugai's rEPO may have used Amgen's starting materials, but,
Amgen's host cells are not covered under a process patent claim; there-
fore, the patented host cells are not protected under section 337 of the
OTCA. 145
IV. THE INADEQUACIES OF THE OTCA
The Amgen decision illustrates the minimal protection accorded by
the OTCA. By confining its scope exclusively to process claims, 1 40 the
OTCA inadequately addresses the problems it was designed to rectify.
A. THE OTCA FAILS TO ENCOURAGE INNOVATION & INDUSTRY
Despite Congress' intention to use the OTCA to protect United
States intellectual property rights and to encourage the development of
new American technology, 147 the legislation has had a disappointing
effect upon American industry. 14 8 As illustrated by Amgen v. Chugai,
the OTCA has two different standards of intellectual property protec-
tion.149 The OTCA guards against the infringement of process pat-
ents,1 50 while abandoning patents lacking a process claim. Inventors
can not prevent the importation of a product made abroad by a process
which uses a starting material patented in the United States."' This
type of relief from patent infringement is neither consistent, adequate,
nor does it promote the OTCA's policy to safeguard intellectual prop-
erty rights. The inconsistency of American intellectual patent law re-
sults in both disfavor and distrust in the effectiveness of a patent. Fur-
142. Id. at 139.
143. Id.
144. Id. at
145. Id. at 1540. The court vacated the Commission's Order which dismissed the
claim for lack of jurisdiction, and remanded the case for entry of a final determination
dismissing the complaint on the merits. Id. The ITC should have made a determination
that Amgen's patent did not cover a process claim. Instead, they refused to hear it. Id.
146. Id. at 1537.
147. Clark, supra note 104, at 1511.
148. Id.
149. Amgen, Inc., 902 F.2d at 1540.
150. Id.; see Clark, supra note 104, at 1151.
151. Amgen, Inc., 902 F.2d at 1540.
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thermore, current patent law places an unfair burden on inventors by
forcing them to obtain process patents in order to properly guard their
invention. These factors hinder rather than bolster American ingenuity.
Inadequate patent protection translates into a tremendous loss of rev-
enue for American industry.1 52 The biotechnology industry, whose com-
mercial success depends upon a patent's ability to generate income, 1 3
is especially vulnerable. Without adequate patent protection, biotech-
nology companies are likely to lose much of their income.154 The
OTCA has the potential to harm the very industry Congress intended
to protect.155 As a result, American competitiveness in the international
marketplace will be inhibited in an era when the trade deficit'56 is soar-
ing and American leadership'"1 in world markets is diminishing.
The OTCA also fails to promote the Constitutional goal of encourag-
ing the arts and sciences.' 58 Congress chose to stimulate innovation by
granting patent rights. 5 Inadequate patent rights restrain the develop-
ment of innovation in industries such as biotechnology. 60 Thus, the
minimal protection provided by OTCA discourages, rather than en-
courages, the development of particular arts and sciences.
The OTCA is inadequate because it fails to provide infringement
remedies for imported products that use patented starting materials
abroad. The failure to provide these remedies brings irreparable conse-
quences - it deters innovation, exposes biotechnological companies to
financial ruin, and harms the American economy.
152. BURRILL, supra note 1, at 94.
153. Id.; see also Perry, supra note 40, at 57 (noting increased recognition in the
value of patents).
154. See supra notes 50-56 (demonstrating the importance of patents to the contin-
ued success of the biotechnology industry).
155. See Bus. WEEK, supra note 49, at 35 (stating that innovation is a weapon of
economic leadership and that laws should encourage economic leadership by protecting
American ingenuity).
156. See Freadhoff, August Trade Deficit Expanded, Reflecting Higher Oil Import
Bill, INVESTOR's DAILY, INC., Oct. 19, 1990, at 25 (stating that the trade deficit for
August 1990 was $9.34 billion). Analysts predict a $12 billion monthly deficit soon. Id.
157. See Bus. WEEK, supra note 49, at 35. (indicating that the fall in American
leadership is evidenced by a decline in capital investments, funding of industrial re-
search, and import penetration of domestic markets). According to renowned political
scholar Don E. Kash, if America does not exploit its scientific assets more efficiently,
the nation's competitiveness will gradually erode or there will be a severe economic
disruption. Id.
158. U.S. CONsT. art. I, § 8, cl. 6.
159. See supra notes 35-43 and accompanying text (describing the rationale behind
Congress' decision to use patent rights to stimulate innovation).





The holding in Amgen v. Chugai evinces a significant weakness in
patent laws that were drafted prior to the emergence of the biotechnol-
ogy industry. 16' Congress is considering amending the OTCA with the
Process Patent Amendments of 1990.162 This proposal attempts to meet
the contemporary needs of the biotechnical industry.16 3
The Process Patent Amendments empower the ITC to ban foreign
products that are made using a biotechnological material covered by a
United States patent.' The proposed amendments would allow the
ITC to exclude imported products that are made, produced, or
processed using a biotechnological material covered by a valid and en-
forceable United States patent.165 Unlike prior legislation, this proposal
would also make infringement claims actionable in a district court. 166
The OTCA must be amended in an effort to provide effective regula-
tion of intellectual property rights. 6 7 The Process Patent Amendments
provide an opportunity to protect American industry against unfair for-
eign patent infringement by expanding intellectual property rights so
that patents on novel starting materials are guarded. 68
Although the proposed amendments are beneficial to United States
industry, 69 they are likely to arouse strong opposition from other trad-
ing nations.' 7 0 The enactment of stronger intellectual property laws
161. Amgen, Inc., 902 F.2d at 1540. The Federal Circuit noted:
[i]t is our impression from study of this case that the possibility of doing what
Chugai is doing in Japan - using Amgen's patented host cells - is something
which was not considered by the Congress in connection with the 1988 revision
of section 1337. Consequently it did nothing to deal with the situation, which it
certainly did not discuss.
Id. Commentators suggest that because biotechnology is a novel industry, it requires
novel legal solutions. Brannigan, Biotechnology and the Law, 16 HorsrA L. REV. 545,
546 (1988).
162. H.R. 3957, 101st Cong., 2d Sess., 165 CONG. REC. 16,746 (1990); see also
Hearings, supra note 22 (describing the debate over the need for additional protection
for the biotechnology industry).
163. H.R. 3957, 101st Cong., 2d Sess., 165 CoNG. REC. 16,746 (1990).
164. Id.
165. H.R. 5664, 101st Cong., 2d Sess., 136 CONG. REc. 116 (1990).
166. Id.
167. See Bonito Boats, Inc. v. Thunder Craft Boats, Inc., 489 U.S. 141, 168 (1989)
(prohibiting the state of Florida from providing a patent for boat hulls). Federal pre-
emption of patent laws limits most state action in this area, and Congress therefore has
the burden to impose effective regulation. Id.
168. H.R. 3957, 101st Cong., 2d Sess., 165 CONG. REC. 16,746 (1990).
169. See Hearings, supra note 22 (arguing that American industry must be pro-
tected from inherent violations of intellectual property law).
170. Bello & Homer, United States Trade Law and Policy Series No. 16: Settling
Disputes in the GATT the Past, Present and Future, 24 INT'L L. 519, 529 (1990)
[hereinafter Bello & Homer]. Trading partners have protested prior changes to section
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could breach United States international obligations under the General
Agreement on Tariffs and Trade17 1 (GATT).17 2 The United States has
taken measures to ensure that the OTCA conforms with GATT provi-
sions. 173 An amendment, however, that safeguards United States indus-
try and patents against foreign manufacturers may be construed as dis-
criminatory against other nations. 17 4
Nevertheless, the fear of opposition is not a sufficient reason to aban-
don the Process Patent Amendments. Large parts of the world are not
subject to GATT rules.7 5 Moreover, GATT dispute settlement mecha-
nisms do not provide adequate protection for the United States.17 6
GATT is also ineffective in terms of expediency and enforceability.17 7
Furthermore, GATT's deficiencies will not be remedied soon. 7 8 Mem-
bers of the GATT negotiating group on trade-related intellectual prop-
erty rights disagree on the strategy that should be taken in resolving
patent piracy problems. 7 The United States can not relinquish unilat-
eral methods of protecting American industry and settling trade dis-
putes absent a showing that GATT is an effective and timely forum for
the redress of unfair trade practice complaints. 80 Because the interna-
tional community fails to provide an operative method of preventing
unfair trade acts, Congress must amend the OTCA to reflect adequate
intellectual property right protection.
CONCLUSION
In passing the OTCA, Congress ventured to protect American inge-
nuity in a global marketplace. The court's ruling in Amgen, however,
337 of the OTCA claiming that the changes are not compatible with article III of the
General Agreement on Tariffs and Trade. Id.
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Such a proposal, however, has received a great deal of criticism. Id.
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not governed by internationally-recognized rules. Id.
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MIST, Sept. 22, 1990, at 20.
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demonstrates that this goal will not be realized under the current legis-
lative scheme. While section 337 protects the claims of a process paten-
tee, it does not defend other types of claims, such as patented bi-
otechnological starting materials. This deficiency in trade law leaves
patents prey to foreign avarice.
The inadequacy of protection provided by American trade and intel-
lectual property laws is detrimental to society. Such minimal intellec-
tual property protection inhibits innovation, threatens the financial sta-
bility of biotechnology companies, and stifles the growth of the
American economy. In addition, consumers suffer the ultimate loss in
foregone product innovation. Resolution of these issues will determine
the development and availability of a broad range of biotechnological
products. Innovation, creativity, and risk-taking must be nurtured and
rewarded in the global marketplace. Congress must amend the OTCA
to reflect just protection for patents.
